Partner Insight: 3 lessons for an uncertain environment

T. Rowe Price's David Eiswert outlines his rule of 3 for the current environment and how he’s excited about new opportunities emerging

clock • 3 min read
David J. Eiswert, Portfolio Manager at T. Rowe Price
Image:

David J. Eiswert, Portfolio Manager at T. Rowe Price

So the first thing I would say is that if you think about why we're not in a deep recession right now, it's because we didn't have a credit cycle. There is no credit cycle, right. And so keep that in your mind like if you don't have a credit cycle it's hard to have a really bad recession, right. So I think when you think about that, think about if I'm really going to get bearish is this should I buy the dip. There's a lot of great companies in there. Do you have a shopping list or the things you want to buy? Because if we don't get a credit cycle, it's a good time to look, to be looking and see if there's good things to buy. That's what I'm going to do, right? So pay attention to this idea of where we have a credit cycle.

The second thing is that, like, are we on a different equilibrium path, right. So will inflation keep inflation higher than it's been? And do you know how to invest in that environment? Because what I find is that most people haven't really, really most people in their career, if you're sitting here today, right, in 2023, in your career, you've never experienced an environment different than secular stagnation. You're basically hard wired for the Fed to cut. That's why there are like seven cuts priced in the next year, right?

 

This post was funded by T. Rowe Price

Important Information

For professional clients only. Not for further distribution.

This material is being furnished for general informational purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, and prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date noted on the material and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request.

It is not intended for distribution to retail investors in any jurisdiction.

This material is issued and approved by T. Rowe Price International Ltd, 60 Queen Victoria Street, London, EC4N 4TZ which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only.

© 2023 T. Rowe Price. All rights reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the bighorn sheep design are, collectively and/or apart, trademarks or registered trademarks of T. Rowe Price Group, Inc.

More on Investment

Daniel Koller (pictured) is head portfolio manager at BB Biotech.

Daniel Koller: Three decades of biotech evolution

US still offering the most biotech names

Daniel Koller
clock 08 January 2024 • 4 min read
Stories of the Week: New Year Honours; Fundsmith slips down ii list; Another short position against Hargreaves Lansdown

Stories of the Week: New Year Honours; Fundsmith slips down ii list; Another short position against Hargreaves Lansdown

The biggest stories from the world of investment and asset management this week: New Year Honours; Fundsmith; Hargreaves Lansdown

Sarka Halas
clock 05 January 2024 • 1 min read
Partner Insight: Outlook 2024 from Royal London Asset Management

Partner Insight: Outlook 2024 from Royal London Asset Management

Royal London Asset Management
clock 03 January 2024 • 1 min read
Trustpilot